Skip to main content
OpenTrials
Completed

NCT Number: NCT04508777

COVID SAFE: COVID-19 Screening Assessment for Exposure

In order to safely and effectively reopen businesses and universities across the US, institutions will need to develop approaches to rapidly identify COVID-19 cases and manage their spread while balancing program effectiveness, feasibility, costs, and scalability.

This study will evaluate the implementation of a COVID-19 screening program that coordinates several existing systems at the University of Pennsylvania including saliva-based viral testing.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Penn Medicine

Philadelphia, Pennsylvania, 19103, United States

About this study

The coronavirus disease 2019 (COVID-19) pandemic has resulted in close to 10,000,000 reported cases worldwide, including more than 2,000,000 aggregated reported cases and 120,000 deaths in the United States. Initial efforts to address the COVID-19 pandemic were aimed at testing symptomatic individuals, implementing stay-in-place orders, and at increasing hospital capacity to meet surge demands. While nations continue to confront the current crisis, plans for the future must be put in place tools to enhance our ability to conduct effective screening, containment, and case management.

Widespread COVID-19 testing is needed to safely and effectively reopen schools and businesses across the US. However, currently approved testing options require reagents that are limited in supply, severely hindering scalability. Emerging evidence indicates that saliva testing with the option of at-home sample collection can accurately identify COVID-19 viral infection. Additional diagnostic testing options will continue to increase patient access. Moreover, this approach provides an option for the easy, safe and convenient collection of samples required for testing without traveling to a doctor's office, hospital, or testing site. Collection by the patient also reduces exposure of health care workers to the virus and preserves limited personal protective equipment.

With access to expanded testing, health systems and universities will need to test alternative methods to manage COVID-19 spread while balancing program effectiveness, feasibility, costs, and scalability. Insights from the field of behavioral economics offer promise for designing and sustaining these kinds of policies. For these reasons, the investigators propose to evaluate the implementation of a COVID-19 screening program that uses saliva-based testing.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be 18 years or older
  • University of Pennsylvania faculty, staff, or trainee
  • Have a phone or device capable of receiving text messages
  • Willing to participate in the study for 6 months

Exclusion criteria

  • Participants will not be eligible if they identify any reason they are unable to participate in the study.

Treatment and study plan

Saliva-based testing

Behavioral

Participants will take part in a voluntary COVID-19 screening program that includes bi-weekly saliva-based testing.

Primary outcomes

  1. Test compliance

    Time frame: 3 months

    The rate of compliance with saliva-based testing

Other outcomes

  1. Test compliance

    Time frame: 6 months

    The rate of compliance with saliva-based testing

Sponsors and collaborators

Lead sponsor

University of Pennsylvania

Other

Registry information

Acronym: COVID SAFE

Important dates

Study start
2020
Primary completion
2020
Study completion
2021
First posted
Aug 11, 2020
Registry last updated
Mar 2, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.